Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUNDTRACK-F1: Surovatamig + Rituximab vs Chemoimmunotherapy in Untreated Follicular Lymphoma
NCT06549595Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Nov 2031
- Countries
- 25
01
Overview
A Phase 3 trial of surovatamig in follicular lymphoma (FL), sponsored by AstraZeneca. Started Aug 2024; status: recruiting.
02
Drugs
surovatamig
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06549595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549595.